BRCA2 and neoplasm: Consistent with the results in the database, compared with the AURKB protein level of tumor samples from cancer patients with intact BRCA2, the AURKB protein level of the tumor samples from cancer patients with mutant BRCA2 was decreased, and the same results were obtained for immunohistochemistry of NSFL1C (Figure 6, C and D).